{
    "root": "433d9d03-a36e-42c6-8e4d-f333ed60e45a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Oxcarbazepine",
    "value": "20250301",
    "ingredients": [
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "OXCARBAZEPINE",
            "code": "VZI5B1W380"
        }
    ],
    "indications": "oxcarbazepine tablets indicated monotherapy adjunctive therapy treatment partial-onset seizures adults monotherapy treatment partial-onset seizures pediatric patients aged 4 years , adjunctive therapy pediatric patients aged 2 years partial-onset seizures .",
    "contraindications": "adults : initiate dose 600 mg/day , given twice day \u2022 adjunctive therapy : maximum increment 600 mg/day approximately weekly intervals . recommended daily dose 1200 mg/day ( 2.1 ) \u2022 conversion monotherapy : withdrawal concomitant 3 6 weeks ; reach maximum dose oxcarbazepine tablets 2 4 weeks increments 600 mg/day weekly intervals recommended daily dose 2400 mg/day ( 2.2 ) \u2022 initiation monotherapy : increments 300 mg/day every third day dose 1200 mg/day ( 2.3 ) \u2022 initiate one-half usual starting dose increase slowly patients creatinine clearance < 30 ml/min ( 2.7 ) pediatrics : initiation 8 10 mg/kg/day , given twice day . patients aged 2 < 4 years 20 kg , starting dose 16 20 mg/kg/day may considered . recommended daily dose dependent upon patient weight . \u2022 adjunctive patients ( aged 2 16 years ) : patients aged 4 16 years , target maintenance dose achieved 2 weeks ( 2.4 ) . patients aged 2 < 4 years , maximum maintenance dose achieved 2 4 weeks exceed 60 mg/kg/day ( 2.4 ) \u2022 conversion monotherapy patients ( aged 4 16 years ) : maximum increment 10 mg/kg/day weekly intervals , concomitant antiepileptic drugs ( aeds ) completely withdrawn 3 6 weeks ( 2.5 ) \u2022 initiation monotherapy patients ( aged 4 16 years ) : increments 5 mg/kg/day every third day ( 2.6 )",
    "warningsAndPrecautions": "oxcarbazepine tablets , usp provided : 300 mg film-coated tablets : brown colored , oval shaped , biconvex , film coated tablets debossed ' v ' one side ' 7 ' ' 7 ' another side separated score line ( functional scoring ) sides . bottle 120 ndc 82804-209-72 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . dispense tight container ( usp ) .",
    "adverseReactions": "oxcarbazepine tablets contraindicated patients known hypersensitivity oxcarbazepine components , eslicarbazepine acetate [ ( 5.2 , 5.3 ) ] .",
    "indications_original": "Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.",
    "contraindications_original": "Adults : initiate with a dose of 600 mg/day, given twice a day \u2022 Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1200 mg/day ( 2.1 ) \u2022 Conversion to Monotherapy: Withdrawal concomitant over 3 to 6 weeks; reach maximum dose of oxcarbazepine tablets in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day ( 2.2 ) \u2022 Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day ( 2.3 ) \u2022 Initiate at one-half the usual starting dose and increase slowly in patients with a creatinine clearance < 30 mL/min ( 2.7 ) Pediatrics : initiation with 8 to 10 mg/kg/day, given twice a day. For patients aged 2 to < 4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight. \u2022 Adjunctive Patients (Aged 2 to 16 Years): For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks ( 2.4 ). For patients aged 2 to < 4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not exceed 60 mg/kg/day ( 2.4 ) \u2022 Conversion to Monotherapy for Patients (Aged 4 to 16 Years): Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs (AEDs) can be completely withdrawn over 3 to 6 weeks ( 2.5 ) \u2022 Initiation of Monotherapy for Patients (Aged 4 to 16 Years): Increments of 5 mg/kg/day every third day ( 2.6 )",
    "warningsAndPrecautions_original": "Oxcarbazepine Tablets, USP are provided as:    \n                     300 mg Film-Coated Tablets:Brown colored, oval shaped, biconvex, film coated tablets debossed with 'V' on one side and '7' and '7' on another side separated by a score line (functional scoring) on both sides.      Bottle of 120\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0NDC 82804-209-72    \n                     \n                       Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Dispense in tight container (USP).",
    "adverseReactions_original": "Oxcarbazepine tablets are contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate [     see Warnings and Precautions (       5.2,       5.3)     ]."
}